AJAmanda M. Johnson

Amanda M. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amanda M. Johnson has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Performance of Google NotebookLM for AI-assisted data extraction and consensus statement generation in a heterogenous systematic review on inflammatory bowel disease, obesity, and cardiometabolic comorbidities: A Methodological Report (Preprint)

    by Sami Samaan, Jalap Devi, Matthew Vincent, Shannon Coombs, Priya Sehgal, Mouhand Mouhamed, Victoria Rai, Amanda M Johnson, Andres J Yarur, Edward L Barnes, et al.

    BACKGROUND Large language models (LLMs) offer promise for systematic review data extraction, but performance in complex multidisciplinary domains and utility for clinical statement generation remain insufficiently described. OBJECTIVE To evaluate Google NotebookLM for AI-assisted data extraction and RAND/UCLA consensus statement generation in a systematic review of IBD, obesity, and cardiometabolic comorbidities. METHODS Studies were organized into domain-specific notebooks; structured prompts generated standardized evidence tables. Two independent reviewers validated outputs against full-text articles using a four-category error classification. Cell-level accuracy and critical accuracy (cells free of major factual errors) were the primary metrics; workflow time was compared against a published conventional extraction benchmark. Concordance between AI-generated and expert-finalized statements was assessed. RESULTS Across 57 articles, 1,710 data cells were extracted; 151 (8.83%) were flagged, yielding 91.17% cell-level accuracy. Major factual errors occurred in only 4 cells (0.23%), for a critical accuracy of 99.77%. Most errors were minor omissions (59.6%) or incomplete extractions (30.5%); domain error rates ranged from 7.08% to 11.33%. The pipeline required 17.7 versus a projected 165.1 person-hours (89.3% reduction). PICO-structured prompting generated 70 candidate statements; 58 of 112 finalized panel statements (51.8%) were AI-derived, and 85.7% were retained in the finalized set. CONCLUSIONS Google NotebookLM demonstrates feasibility as a primary extraction and synthesis tool in a multidisciplinary systematic review, with extractive incompleteness as the principal limitation and substantial time savings over conventional approaches. Its novel application to RAND/UCLA consensus statement generation extends AI-assisted evidence synthesis to clinical consensus generation workflow.


  • Open Access

    Performance of Google NotebookLM for AI-assisted data extraction and consensus statement generation in a heterogenous systematic review on inflammatory bowel disease, obesity, and cardiometabolic comorbidities: A Methodological Report

    by Sami Samaan, Jalpa Devi, Matthew Vincent, Shannon Coombs, Priya Sehgal, Mouhand Mouhamed, Victoria Rai, Amanda M Johnson, Andres J Yarur, Edward L Barnes, et al.

    Background: Large language models (LLMs) offer promise for systematic review data extraction, but performance in complex multidisciplinary domains and utility for clinical statement generation remain insufficiently described. Objectives: To evaluate Google NotebookLM for AI-assisted data extraction and RAND/UCLA consensus statement generation in a systematic review of IBD, obesity, and cardiometabolic comorbidities. Methods: Studies were organized into domain-specific notebooks; structured prompts generated standardized evidence tables. Two independent reviewers validated outputs against full-text articles using a four-category error classification. Cell-level accuracy and critical accuracy (cells free of major factual errors) were the primary metrics; workflow time was compared against a published conventional extraction benchmark. Concordance between AI-generated and expert-finalized statements was assessed. Results: Across 57 articles, 1,710 data cells were extracted; 151 (8.83%) were flagged, yielding 91.17% cell-level accuracy. Major factual errors occurred in only 4 cells (0.23%), for a critical accuracy of 99.77%. Most errors were minor omissions (59.6%) or incomplete extractions (30.5%); domain error rates ranged from 7.08% to 11.33%. The pipeline required 17.7 versus a projected 165.1 person-hours (89.3% reduction). PICO-structured prompting generated 70 candidate statements; 58 of 112 finalized panel statements (51.8%) were AI-derived, and 85.7% were retained in the finalized set. Conclusion: Google NotebookLM demonstrates feasibility as a primary extraction and synthesis tool in a multidisciplinary systematic review, with extractive incompleteness as the principal limitation and substantial time savings over conventional approaches. Its novel application to RAND/UCLA consensus statement generation extends AI-assisted evidence synthesis to clinical consensus generation workflow.

  • Evaluating the Impact of Visceral Adiposity and Sarcopenia on Outcomes in Hospitalized Patients with Acute Severe Ulcerative Colitis

    by Prajith Raj Ramesh, Robert P. Hartman, William S. Harmsen, Jason Klug, Joao Miranda, Abhinav Vasudevan, Edward V. Loftus, John V. Thomas, Amanda M. Johnson

    Purpose Predicting outcomes in acute severe ulcerative colitis (ASUC) is challenging. Data suggest visceral adiposity may negatively impact ulcerative colitis outcomes. We aimed to evaluate the impact of visceral adiposity and sarcopenia on ASUC outcomes. Methods Patients hospitalized for ASUC with available abdominopelvic CT imaging within 3 months of admission were retrospectively reviewed. Automated segmentation of subcutaneous adipose tissue (SAT) and visceral adipose tissue(VAT) at the third lumbar vertebrae was performed and reviewed by expert radiologists in Visage AI Accelerator. The primary outcome was colectomy during index hospitalization based on quartiles of VAT and visceral fat index (VFI) (VAT:SAT), sarcopenia, and sarcopenic obesity. Secondary outcomes aimed at assessing response to intravenous corticosteroids (IVCS) and infliximab (IFX). Univariate and multivariate associations with the risk of colectomy at index hospitalization were examined using logistic regression models. Results A total of 90 patients (64.4% male, median age 36.5 years) were identified. During the index hospitalization, 32 patients (35.6%) required colectomy. Response to IVCS and IFX was seen in 54.2% (45/86) and 66.7% (18/27) patients, respectively. There were no significant differences in the risk of colectomy, response to IVCS or IFX based on VAT area or VFI. Sarcopenia was associated with a reduced likelihood of IVCS response (HR 0.33; 95% CI 0.11–0.97; p = 0.045). Prior advanced therapy exposure was associated with an increased risk of colectomy (HR 7.95; p < 0.001) and decreased response to IVCS (HR 0.35; p = 0.041) on multivariate analysis and decreased response to IFX on univariate analyses (OR 0.16; p = 0.072). Conclusion In this cohort, neither visceral adiposity nor sarcopenia significantly impacted the colectomy risk, while sarcopenia was associated with a reduced likelihood of corticosteroid response. Prior advanced therapy exposure negatively impacted all outcomes.


  • A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease

    by Amanda M Johnson, Manar Askar, Seema Belani, Abdul Khan, Anthony A Xu, Blake Kassmeyer, Hyder Said, Michael Santiago-Castro, Jalpa Devi, Katherine Huang, et al.

    Background: We aimed to evaluate the effectiveness and safety of risankizumab (RZB) for Crohn’s disease (CD) in routine clinical practice. Methods: We performed a retrospective review of a multicenter consortium of CD patients treated with RZB. Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of ≤4 or physician global assessment in those without HBI or with ileostomy) and 6-month endoscopic remission (Simplified Endoscopic Mucosal Assessment for Crohn’s Disease of 0-1 or absence of ulcers). Secondary outcomes included steroid-free clinical remission, clinical response, radiographic response, cumulative clinical and endoscopic remission rates at 6 and 12 months, and adverse events. Results: A total of 309 patients were included (median disease duration 14 years [IQR, 6-24]; median follow-up 7.1 months [IQR, 4.1-10.3]). Most patients (85.8%) were advanced therapy (AT)-exposed, and 169 (54.7%) had prior ustekinumab (UST) exposure. Week 12 clinical remission rates were 49.7% (98/197) overall, and 44.2% (50/113) vs 57.1% (48/84) in UST-exposed vs naïve patients (P = .073). Among those with active disease on baseline endoscopy (n = 122) who had an available follow-up at 6 months, 52.4% (22/42) achieved endoscopic remission. Cumulative rates of clinical and endoscopic remission at 12 months were 65.0% and 49.5%, respectively. Cumulative 12-month endoscopic remission was 33.9% (19/56) in UST-exposed and 68.1% (32/47) in UST-naïve patients (P < .001). Risankizumab was well-tolerated with no new safety signals identified. Conclusions: In this large multicenter cohort of patients with CD, RZB was well-tolerated and effective in achieving favorable clinical and endoscopic outcomes in both AT-exposed and naïve populations, including those with exposure to UST.


  • A Curious Case of Colitis

    by Elida Voth, Amanda Johnson


  • Reviewing the impact of obesity on inflammatory bowel disease and considerations for optimizing management

    by Wissam Ghusn, Edward V. Jr. Loftus, Amanda M. Johnson

    Purpose of review: This review examines the complex relationship between obesity and inflammatory bowel disease (IBD), encompassing their potentially shared pathogenesis, the impact of obesity on the natural history and treatment outcomes of IBD, and the management of obesity in the patient with IBD. Recent findings: Obesity represents a state of chronic inflammation that may not only contribute to IBD pathogenesis, but also influence disease progression, complications, and response to treatment. Increased visceral adiposity may carry negative prognostic implications for disease and treatment-specific outcomes. Antiobesity medications, endoscopic bariatric therapies, and even bariatric surgery may be effective and well tolerated in selected patients with IBD. Summary: The intersection of obesity and IBD presents a significant clinical challenge, with obesity influencing the natural history of IBD and potentially affecting treatment efficacy. As obesity prevalence among IBD patients rises, a tailored approach to management is crucial, taking into account the individualized risks and benefits of various treatment strategies, including lifestyle interventions, pharmacotherapy, endoscopic procedures, and bariatric surgery.


  • Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data

    by Amanda M. Johnson, Edward V. Loftus

    Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and more recently moderate-to-severe Crohn's disease (CD). After examining the current landscape of CD management including therapies which are currently approved and those in late stages of development, we will review the interleukin pathway and discuss the specific mechanism of targeted IL-23 inhibition, summarize available clinical trial data on efficacy and safety of Risankizumab, consider future positioning of Risankizumab in the therapeutic armamentarium, and ultimately discuss future needs for the field. Risankizumab represents the first and only targeted IL-23 inhibitor approved for the treatment of CD, providing a promising addition to the therapeutic armamentarium for CD, with a favorable safety profile and demonstrated efficacy in both biologic-naïve and exposed populations. It is possible that the targeted nature of Risankizumab may enhance efficacy and safety over combined IL-12/23 inhibition, with trials underway attempting to shed light on that hypothesis.


  • Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease

    by Jonathan T. Pham, Wissam Ghusn, Andres Acosta, Edward V. Loftus, Amanda M. Johnson

    INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of −6.9 ± 8.3 and −8.1 ± 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.


  • Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn’s Disease

    by Amanda M. Johnson, William Scott Harmsen, Satimai Aniwan, William J. Tremaine, Laura E. Raffals, Barham K. Abu Dayyeh, Edward V. Jr Loftus

    Background: Obesity is on the rise within the inflammatory bowel disease population. The impact obesity has on the natural history of Crohn’s disease (CD) is not well-understood. We aimed to describe the prevalence of obesity in a population-based cohort of newly diagnosed patients with CD, and the impact obesity had on disease phenotype and outcomes of corticosteroid use, hospitalization, intestinal resection, and development of fistulizing or penetrating disease. Materials and Methods: A chart review was performed on Olmsted County, Minnesota residents diagnosed with CD between 1970 and 2010. Data were collected on demographics, body mass index, CD location and behavior, CD-related hospitalizations, corticosteroid use, and intestinal resection. The proportion of individuals considered obese at the time of CD diagnosis was evaluated over time, and CD-associated complications were assessed with Kaplan-Meier survival analysis. Results: We identified 334 individuals diagnosed with CD between 1970 and 2010, of whom 156 (46.7%) were either overweight (27.8%) or obese (18.9%) at the time of diagnosis. The proportion of patients considered obese at the time of their diagnosis of CD increased 2-3 fold over the course of the study period. However, obesity did not have a significant impact on the future risk of corticosteroid use, hospitalization, intestinal resection, or development of penetrating and stricturing complications. Conclusions: Obesity is on the rise in patients with CD, although in this cohort, there did not appear to be any negative association with future CD-related outcomes. Further prospective studies, ideally including obesity measures such as visceral adipose tissue assessment, are warranted to understand the implications of the rising prevalence of obesity on CD outcomes.


  • Endoscopic Bariatric Therapies for the Management of Obesity in Patients with Inflammatory Bowel Disease

    by Amanda M. Johnson, Andrew C. Storm, Tala Mahmoud, Rabih Ghazi, Babusai Rapaka, Donna M. Abboud, Edward V. Loftus, Barham K. Abu Dayyeh